# Biosimilars' Role in Expanding Global Access to Psoriasis Treatment Biosimilars are **highly effective and safe alternatives** to originator biologic drugs for psoriasis, offering substantial cost reductions and improved access to treatments that were previously unaffordable for many patients.[2][3] ## How Biosimilars Improve Access Biosimilars are FDA-approved biologic products that are very similar to existing reference biologics, with no clinically meaningful differences in safety or eff

**Hoffnung für seltene Psoriasis-Form** Eine seltene und schwere Psoriasis-Form lässt sich besser behandeln als bisher gedacht. Forscher aus Bayern untersuchten 29 Patienten. Die meisten erhielten biologische Medikamente. Bei allen Patienten verbesserte sich die Erkrankung deutlich. Die Messwerte der Schwere sanken stark. Besonders wirksam sind Medikamente gegen die Botenstoffe IL-17 und IL-23. Einige Patienten wurden sogar ganz gesund. Ältere Medikamente verursachten mehr Nebenwirkungen. Ärzte

Biosimilars demonstrate **comparable efficacy and safety to originator biologics** for moderate-to-severe psoriasis while offering substantially lower costs, creating significant potential to expand treatment access in low- and middle-income countries where price barriers currently restrict patients' access to effective treatments.[1][2][5] **Clinical Equivalence Confirmed** A systematic review of 14 randomized clinical trials and 3 cohort studies found no clinically or statistically significa

I notice that while your query references a specific cross-sectional survey on patient attitudes toward digital health interventions in dermatology, the full study details aren't included in the search results provided. However, I can share what the search results reveal about **dermatological patients' attitudes toward digital health interventions**: ## Patient Acceptance and Interest Patients generally show **positive attitudes and interest in digital health tools**, though their actual adop

# Zusammenfassung der MED-PSO Studie Die Studie untersuchte, wie sich schwer zu behandelnde Schuppenflechte-Flecken von klassischen unterscheiden – insbesondere welche Gene aktiviert sind, wie das Immunsystem reagiert und welche Moleküle eine Rolle spielen. Das Hauptziel war zu verstehen, warum manche Patienten schlecht auf die bisherige Therapie ansprechen, und zu testen, wie effektiv ein neues Medikament gegen diese schweren Fälle wirkt. ## Die untersuchte Substanz Das Medikament **Deucrava

Diese Studie untersucht ein neues Medikament namens Zasocitinib zur Behandlung von Plaque-Psoriasis bei Kindern und Jugendlichen im Alter von 4 bis unter 18 Jahren. Es handelt sich um eine Phase-3-Studie, die die Wirksamkeit, Sicherheit und Verträglichkeit des Medikaments prüft, indem es mit einem Placebopräparat verglichen wird. Die Studie ist randomisiert (die Teilnehmer werden zufällig einer Gruppe zugeordnet), multizentrisch (findet an mehreren Orten statt) und doppelblind (weder die Teilneh

# HeROPA-Studie: HRO350 bei Psoriasis Die HeROPA-Studie war eine randomisierte, doppelblinde, placebokontrollierte Phase-2B-Studie, die die Wirksamkeit und Sicherheit von HRO350 bei leichter bis mittelschwerer Psoriasis untersucht hat. An der Studie nahmen über 500 Patienten in fünf europäischen Ländern teil. Das Ziel war es, festzustellen, ob HRO350 wirksam gegen Psoriasis-Symptome ist und welche Dosis am besten funktioniert. Nach dem primären Endpunkt bei 26 Wochen zeigte sich eine unerwartet

# Zusammenfassung der Studie Diese Studie untersuchte die Sicherheit, Verträglichkeit und Wirkungsweise eines neuen Medikaments namens SUDO-286 bei Menschen mit Schuppenflechte (Psoriasis). Das Medikament wurde als Creme oder Lotion direkt auf die Haut aufgetragen. Die Forscher wollten herausfinden, ob das Mittel gut vertragen wird, welche Nebenwirkungen auftreten können und wie es im Körper wirkt. ## Die Substanz SUDO-286 SUDO-286 ist ein neuer Wirkstoff, der gezielt ein bestimmtes Protein i

Trial number: 2023-506333-29-00 Overall trial status: Ongoing, recruiting Trial title: A phase 3B exploratory multicenter open-label study to evaluate the effect of bimekizumab on gene expression biomarkers in study participants with moderate to severe plaque psoriasis. Medical conditions: Psoriatic arthritis, Moderate to Severe Plaque Psoriasis Status in each country: Poland:Ongoing, recruiting, Germany:Ongoing, recruiting Trial phase: Phase III and phase IV (Integrated) Therapeutic Areas

Trial number: 2023-506296-97-00 Overall trial status: Ongoing, recruiting Trial title: A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis Medical conditions: Moderate to Severe Plaque Psoriasis Status in each country: Germany:Ongoing, recruiting, Romania:Authorised, recruiting, Italy:Ongoing, recruiting

Trial number: 2023-507415-35-00 Overall trial status: Ongoing, recruitment ended Trial title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1) Medical conditions: Psoriatic Arthritis Status in each country: Czechia:Ended, Germany:Ended, Estonia:Ended, Spain:Ended, Slovakia:Ongoing, recruitment ended, Italy:Ended, Poland:Ended Trial phase: Ther

Conditions: Psoriasis (PsO); Psoriasis Arthritis; Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis); Spondylarthropathies Interventions: Biological: Biologic Agent Sponsors: University Hospital Tuebingen; University Hospital Freiburg; University Hospital Heidelberg; University Hospital Ulm RecruitingKomplette Studien-Angaben zeigen

Psoriasis is a chronic, immune-mediated disorder with strong genetic susceptibility and environmental triggers, characterized by excessive proliferation of keratinocytes and recruitment of inflammatory cells. Affecting 2-3% of the global population and represents a significant public health challenge. In psoriasis, the skin barrier is altered rather than uniformly enhanced, and its permeability varies with drug types and disease states, which may affect the effective delivery of drugs to affecte

Background Psoriasis is an immune-mediated inflammatory skin condition that is chronic and causes a great deal of disease burden, especially for those affected in their most productive years. Gut microbiota, immune parameters and, in turn, psoriasis symptom improvement have recently been associated with the use of probiotics in several different studies.Objectives This study aims to conduct an umbrella review of systematic reviews and meta-analyses of the effectiveness of probiotic supplementati

Psoriasis is a common chronic inflammatory skin disease with a complex pathogenesis that involves the dysregulation of multiple cellular components and interconnected molecular pathways. Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor that integrates signals from multiple cytokines and growth factors to regulate gene expression involved in cell proliferation, survival, and inflammation. Emerging evidence has shown the pivotal role of STAT3 in driving the

Psoriasis is a common, chronic, inflammatory skin disease that affects many patients and exerts a heavy physical and mental burden. Wogonin (WG), derived from the root extract of Scutellaria Baicalensis, has shown therapeutic effects in a variety of inflammatory diseases. However, its specific effects and mechanisms in psoriasis treatment remain poorly understood. This study aimed to investigate the therapeutic effects and underlying mechanisms of WG in psoriasis. In this study, we first identif